Close Menu
Home › Personalis, FLX Bio Sign Research Agreement for Use of Universal Cancer Immunogenomics Platform

Personalis, FLX Bio Sign Research Agreement for Use of Universal Cancer Immunogenomics Platform

May 20, 2019
|
staff reporter

NEW YORK (GenomeWeb) – Personalis said today that it has signed a research agreement with FLX Bio to use its universal cancer immunogenomics ImmunoID Next platform to evaluate therapy-related changes in tumors of advanced cancer patients treated with FLX Bio's FLX475 drug.

As part of the collaboration, FLX Bio will apply the Personalis assay in a patient cohort that is part of a Phase I/II clinical trial evaluating FLX475, a CCR4 antagonist, as monotherapy or in combination with pembrolizumab.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Oct
21
Featured Webinar

Broad Genomic Testing for Oncology Clinical Trials and Clinical Practice

Genomics is a key element in the potential of precision medicine to transform oncology. 

Oct
23
Featured Webinar

Single-Cell Methylation Profiling of Pediatric Tumors via a Unique NGS-based Approach

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries. 

Oct
24
Featured Webinar

Designing, Decoding & Delivering on Genetic Testing for Inherited Disease at Versiti

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

Nov
14
Featured Webinar

High-Performance Variant Detection in Somatic Cancer Testing with an Integrated NGS Solution

Sponsored by
Qiagen

This webinar will discuss some of the issues laboratories face when transitioning to next-generation sequencing, and the key features to be considered for a successful implementation in routine testing.

What's Popular?

In Cancer

  1. Colon Cancer Recurrence Clues Identified in Post-Treatment ctDNA Detection

  2. Inivata Collecting Evidence for Liquid Biopsy in Immunotherapy Prediction, Response Monitoring

    Premium

  3. CHMP Issues Positive Decision for Keytruda in First Line PD-L1 Positive Head, Neck Cancer

    Premium

  4. Exact Sciences, Mayo Clinic Launch Real-World Impact Study for Cologuard

  5. Gut Microbiome May Affect Cancer Patients' Responses to Immunotherapy, Emerging Research Shows

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.